Search

Search Constraints

You searched for: Author/Creator Panebianco, Deborah

Search Results

1. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate. Issue 7 (7th June 2019)

2. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants. Issue 2 (22nd July 2020)

3. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Issue 2 (24th November 2020)

4. Drug‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants. Issue 4 (14th February 2022)

5. Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation. (24th May 2014)

6. Lack of pharmacokinetic interaction between single oral doses of letermovir (MK-8228) and fluconazole in healthy subjects. Issue 1 (January 2019)

7. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. Issue 6 (24th July 2018)

8. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy. Issue 6 (24th July 2018)

9. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers. (8th April 2013)

10. Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. (16th April 2019)